Compare Dolby Laboratories, Inc. (DLB) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Tilray Brands Inc — how do they compare? Dolby Laboratories, Inc. trades at $61.82 (market cap $5.82B), while Tilray Brands Inc trades at $4.78 (market cap $601.34M). The key difference: Dolby Laboratories, Inc. is far larger — about 9.7× Tilray Brands Inc's market cap, and Dolby Laboratories, Inc. pays a 2.32% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| DLB | TLRY | |
|---|---|---|
Market Cap | $5.82B | $601.34M |
Sector | Industrials | Health |
52-Week High | $75.62 | $21.00 |
52-Week Low | $48.51 | $3.88 |
Enterprise Value | $5.19B | $768.47M |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $61.77, up 1.4% today, with a bullish technical trend and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $0.69 versus $0.67 expected. Revenue remains stable around $1.3 billion annually, with robust gross margins of 87.61%. Recent news highlights growth in Dolby Atmos and automotive licensing, though near-term revenue volatility persists.
DLB offers a compelling valuation with a P/E of 26.29 below the analyst target of $87.50, implying significant upside. Key risks include licensing deal timing and competitive pressures in audio-video tech. Institutional sentiment is positive, with 47% of analysts rating it a Buy, but investors should monitor execution on Q4 growth guidance.
TLRY trades at $4.57, up 2.93% with a bullish technical signal, though recent earnings misses and negative profitability metrics highlight fundamental challenges. The company reported record fiscal 2026 revenue of $915 million but continues to post significant net losses. Analyst sentiment is mixed with 25% buy ratings, while technical indicators show RSI near overbought levels with key support at $4.
Outlook remains cautious due to persistent losses and high valuation multiples, though revenue growth and diversification into beverages offer potential upside. Key risks include execution challenges, cannabis regulatory uncertainty, and competitive pressures in the consumer goods space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
